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Abstract 
Alzheimer’s disease affects an ever-increasing number of people in the aging population.  
Current treatment options are limited to a narrow time frame at the mild to moderate stage 
of dementia, and patients are confronted with the inevitable progression of their disease. 
Most investigational drugs fail to prove their efficacy in clinical trials, and there are but a few 
preventative measures that one can take. A novel treatment approach, using 
photobiomodulation to increase the brain’s mitochondrial function and prevent neuronal 
apoptosis, has shown promising results in in vitro and in vivo experiments. This systematic 
review aims at providing a comprehensive summary on the available research on 
photobiomodulation against Alzheimer’s disease to support the translation of this modality 
from bench to bedside. It shows that the mechanistic action has been largely understood on 
a cellular level, safe and effective doses have been found in animal models, and first human 
case studies provide reason to enter large scale clinical trials. A brief outlook on study 
design concludes this review and provides a basis for further work on the topic. 
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1 Introduction 
According to the American Alzheimer’s Association, 11% of older Americans (age 65 and 
older) suffer from Alzheimer’s disease (AD) [1]. There is a similar situation in Austria, where 
about 100 000 people (6.4 % of Austrians aged 65 and older) suffer from AD with a 
prospected growth to 230 000 by the year 2050 [2]. This rise in numbers is mainly caused by 
the aging population, with a prolonged life expectancy and the generation of “Baby-Boomers” 
(people born in the 1950s and 1960s) as driving factors [3]. Affecting such a large number of 
individuals, Alzheimer’s disease is a challenge on the health care system. About one billion 
Euro per year are spent on AD-care in Austria alone [2,4], three quarters of which are non-
medical expenses related to personal assistance in activities of daily life. Aside from being 
costly, AD also claims its toll on the quality of life of caregivers. Compared to people who 
aren’t affected by AD directly or indirectly, those who care for Alzheimer’s patients have 
shown signs of a weaker immune system, more pro-inflammatory proteins, as well as 
significantly shorter telomeres [5]. As of yet there is no medical treatment that can either 
cure, prevent, or completely stop the progression of AD. The lack of treatment options is 
aggravated by a lack of reliable diagnostic tools that could detect the disease before the 
onset of symptoms. The pre-symptomatic period of Alzheimer’s disease may last for 
decades, but once symptoms start to show, there is only a small therapeutic window before 
neurodegeneration renders the affected person completely dependent on external care. 
 
The key to a cure of the disease may still lay in the dark, but there is an increasing amount of 
research being done that suggests that literal enlightenment might pave the way against AD. 
Starting off by simply searching for “low level light therapy Alzheimer’s disease” at the 
PubMed database of the NCBI and using the references within relevant publications, it 
quickly becomes obvious that there are many different names for treatments utilizing light in 
the UV-VIS-NIR range. While Kendric C. Smith suggested us to use the “simple and correct 
term, phototherapy” [6], the scientific consensus recently introduced the term 
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photobiomodulation (PBM) for what used to be called low level laser/light therapy (LLLT) 
[7,8]. As the literature also quickly shows, it seems possible to apply photobiomodulation to 
the brain transcranially, for which even more different terms and abbreviations exist. Figure 1 
provides an overview to the multiple terms describing the same technique. 
 
 
Figure 1: There are many names used for the use of light in medical applications, which can all be grouped under 
the umbrella term of photobiomodulation. Used against Alzheimer’s disease the method utilizes comparatively low 
power, or low level, near-infrared laser or LED light which can be applied in a transcranial manner for photo-
neuro-modulation [9]. 
 
As Table 1 shows, reducing the literature search to the MeSH terms “Photobiomodulation” 
and “Alzheimer’s disease” falls a long way short of what can be found when performing a 
query containing a combination of all search terms from Figure 1 and identifiers for 
Alzheimer’s disease and dementia. There was just one obvious mismatch when using the 
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broader search term and it was easy to identify when “NILT” was found to be used as an 
abbreviation for “Northern Ireland Life and Times”. 
 
Table 1: Comparison of search results in the NCBI PubMed database from a free search containing multiple and 
historic names for photobiomodulation versus MeSH terms only. 
 Combination of terms from 
Figure 1 and an identifier for 
Alzheimer’s disease 
MeSH Terms for AD and PBM 
Total number of results 36 8 
Species: Humans 16 4 
Type: Review article 5 0 
Obvious mismatch 1 0 
 
The 5 Review articles [10–14] come to the conclusion, that photobiomodulation with low level 
red to near infrared light offers a compelling method against neurodegeneration. 
 
 
2 Literature Summary 
Photobiomodulation (PBM) is defined as the use of monochromatic or quasi-monochromatic 
light from a low power laser or LED source to modify or modulate biological functions. Such a 
modulation is based on the presence of chromophores in cells and tissues. These 
chromophores are molecules capable of absorbing light, whose excitation can influence 
further molecules and biochemical pathways with the potential for a therapeutic effect [15]. 
The target molecule of PBM, mainly discussed in literature, lies within Complex IV 
(cytochrome c oxidase) of the mitochondrial respiration system. Photons that interfere with 
the cytochrome oxidase enzyme in the NIR frequency range are absorbed, essentially acting 
as an exogenous supply of highly energized electrons to the mitochondrial respiratory chain. 
Following this immediate, primary effect, the increase in cytochrome oxidase activity triggers 
secondary effects by activating enzymatic pathways which are coupled to the mitochondria’s 
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role in energy metabolism, cell homeostasis, and cell survival signaling. The secondary 
effects of photobiomodulation amplify the primary effects by upregulating the levels of 
cytochrome oxidase and thus creating more of the target molecule for PBM [13,16]. 
The energy density delivered by PBM is generally too low to cause concerns about heating 
and tissue destruction [17], and it appears to be safe even when applied long term [18]. As a 
treatment option for head and neck pain, for treatments of arthritis, and for carpal tunnel 
syndrome, PBM was shown to have an efficacy beyond the placebo effect, [19], which lead 
to the first FDA-approved low-level light therapy devices for pain relief [20]. 
Interest in the use of photobiomodulation for neuro-rehabilitation is growing and it has 
already shown potential in treating traumatic brain injury, stroke, psychiatric disorders, as 
well as neurodegenerative disease in general [21–23]. 
 
1.1 Transcranial Photobiomodulation with Red to Near 
Infra-Red Light 
To make PBM work on the brain, one can benefit from the optical tissue window which allows 
wavelengths of light between approximately 650 nm and 1200 nm to travel through skin and 
skull, i.e. transcranially. The boundaries of the optical tissue window are defined by the 
strong absorption of hemoglobin and water. The penetration depth of wavelengths within 
those boundaries was measured for example by Tedford et al, who achieved a maximal 
penetration depth at a wavelength of 808 nm [24,25]. Wang and Li evaluated this further and 
confirmed 810 nm as well as 660 nm to be the best suitable wavelengths for transcranial 
photobiomodulation [26]. 
Considering an illumination of the brain at even deeper depths without having to open the 
skull, Bungart et al suggest the use of nanoparticles as an alternative light source for PBM 
[27]. These nanoparticles, termed ‘Bioluminescence Resonance Energy Transfer to 
Quantum Dots’ (BRET-Qdots), emit light in the NIR wavelength range when their luciferase 
enzyme is activated with coelenterazine-h substrate. The reported downside to a 
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nanoparticle treatment are concerns about the toxicity of the heavy metal content of the 
BRET-Qdots, which are yet to be fully alleviated. 
 
1 Molecular Mechanisms of Photobiomodulation and their 
Implications for Alzheimer’s Disease 
The impact of photobiomodulation on cell culture and animal models of Alzheimer’s disease 
has been extensively studied. A summary of the progress on each stage of development 
from basic research to preclinical and clinical Phase I and II trials is presented to form the 
base for a treatment plan. 
 
2..1.1 PBM and AD in vitro 
Sommer et al report that photobiomodulation reduces amyloid beta (Aβ25-35) aggregates in 
human neuroblastoma cells [28] and Yang et al observed a reduction in amyloid beta 
induced oxidative and inflammatory responses in rat primary cortical astrocytes [29]. Looking 
further at the implications of PBM on neuro-inflammatory pathways, Song et al observed the 
effects of He-Ne laser light (632.8 nm) at doses from 3 J/cm² to 50 J/cm² on central nervous 
system resident macrophages (Microglia) in human SH-SY5Y neuronal cells and conclude 
that 20 J/cm² at intervals of 24 h was the optimal dose to attenuate cell death by reducing 
microglia-mediated neurotoxicity via the Src/Syk signaling pathways [30]. 
Liang et al and Zhang et al examined the pathways leading to cell apoptosis following Aβ25-35 
aggregation on neuronally differentiated PC12 cells and observed that a treatment with low 
power light produced with a He-Ne Laser at 623.8 nm demonstrated a positive effect of PBM 
[31–33]. Zhang et al specifically report that PBM activates protein kinase B (PKB / Akt) at a 
dose of 2 J/cm², which in turn promotes a series of anti-apoptotic effects such as the 
inhibition of translocation of the pro-apoptotic Yes-associated protein (YAP) from the 
cytoplasm to the nucleus [33]. PBM with a He-Ne Laser also appears to activate protein 
kinase C (PKC), thereby affecting downstream apoptotic proteins in a dose dependent 
manner [32]. Irradiation for 5 to 20 min with an energy density of 0.52 mW/cm², 
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corresponding to a delivered dose from 0.156 J/cm² to 0.624 J/cm², decreases levels of the 
pro-apoptotic Bax and either increases or does not affect levels of the anti-apoptotic Bcl-XL 
as compared to control cells with Aβ25-35 aggregation. This effect was reversed when an 
irradiation time of 40 minutes with 0.52 mW/cm² was reached, corresponding to a delivered 
dose of 1.248 J/cm², which illustrates the dose dependence of PBM when used to counteract 
Aβ-induced cell apoptosis. The reports from Liang et al from their use of a 632.8 nm He-Ne 
Laser at a dose of 2 J/cm² on neuronal PC12 cells with Aβ25-35 aggregation state that PBM 
has a pro-survival effect by acting on the Akt/GSK3b/b-catenin pathway [31]. Building on to 
the hypothesis that amyloid-beta induced neurotoxicity and dendrite atrophy may be a 
consequence of brain-derived neurotropic factor (BDNF) deficiency, Meng et al report that 
ERK can be photo-activated with a 632.8 nm He-Ne laser, delivering doses from 0.5 J/cm² to 
4 J/cm² applied to Aβ25-35-treated human SH-SY5Y cells, which upregulates BDNF in a 
CREB-dependent manner [34]. A summary of the cell signaling effects of photobiomodulation 
described to this point is shown in Figure 2. 
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 Figure 2: Summary of the signaling pathways influenced by photobiomodulation, which appear to inhibit Aβ-
induced nerve cell apoptosis while simultaneously promoting nerve cell survival. 
 
2..1.2 PBM and AD in vivo 
Using a mouse model of Alzheimer’s disease, Farfara et all and Oron et al have shown to 
ameliorate disease progression by stimulating the proliferation of mesenchymal stem cells 
(MSCs) with photobiomodulation [35,36]. Weekly treatments of PBM with a dose of 1 J/cm² 
applied to the bone marrow of AD-mice iappears to increase the MSCs ability to phagocytose 
Aβ-proteins in the brain, which leads to improved cognitive capacity and spatial learning after 
a total treatment duration of 2 months, compared to a sham-treated control group. This is an 
interesting observation, albeit outside the scope of this review, since it builds not on the 
effect of PBM on braincells directly, but rather secondary effects through stimulation of 
MSCs. 
Using two transgenic mouse models for AD, engineered to either develop neurofibrillary 
tangles (NFT) or Aβ-plaques, and treating them for a total of 20 times over the course of four 
weeks with LED light at 670 nm, delivering a dose of 4 J/cm² per treatment, Purushothuman 
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et al demonstrated histochemical evidence of a beneficial effect [37]. NFTs, 
hyperphosphorylated tau-protein, and oxidative stress markers were reduced to near 
wildtype levels and PBM treatment also reduced Aβ-plaques in both number and in size. 
De Taboada et al used a GaAIAs diode laser with a wavelength of 808 nm ± 10 nm to deliver 
increasing doses, from 4.8 J/cm² (1.2 J/cm² at cortical surface) to 48 J/cm² (12 J/cm² at 
cortical surface), three times per week for a total duration of six months on transgenic mice 
engineered to develop Aβ-plaques [38]. Their results show an attenuation of amyloid 
development, leading to the conclusion that an early and regular administration of PBM has 
the potential to halt progression from MCI to AD. 
 
2 Applications of Transcranial Photobiomodulation on Human 
Subjects Supporting its Therapeutic Value for Neurological Use 
In an opinion article by Gonzalez-Lima and Barret [17], the authors summarize how the 
development of photobiomodulation (PBM) has evolved over the last 40 years to a point 
where it is beginning to be used for cognitive-enhancing applications. 
They built a placebo controlled study focusing on the beneficial cognitive and emotional 
effects in humans upon this opinion, and already two weeks after a single therapy session a 
significant improvement was observed [39]. These beneficial effects are reflected in 
improvements in reaction time in a sustained-attention psychomotor vigilance task (PVT), in 
a delayed match-to-sample memory task (DMS), and a self-reported Positive and Negative 
Affect Schedule (PANAS-X). Blanco et al then used the Wisconsin Card Sorting Task 
(WCST) directly after receiving the PBM treatment to assess the effects of transcranial 
infrared laser stimulation on executive function in a placebo controlled study on healthy 
human participants [40]. Here, low level laser light at a wavelength of 1064 nm and power 
density of 250 mW/cm² was applied to two locations on the right portion of the forehead for a 
total of four minutes per site. The total supplied dose of this study again corresponds to the 
ones stated above, being 60 J/cm² per site, and the treatment group performed significantly 
better than the control group during a WCST performed. 
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Schiffer et al report beneficial effects of transcranial PBM on anxiety and depression after a 
study in which PBM with an LED array with a peak wavelength at 810 nm and an energy 
density of also 250 mW/cm² was used [41]. They calculated that from the supplied dose of 
60 J/cm² at the scalp, an effective 2.1 J/cm² (3.7 %) reached the dura of the brain. Positive 
effects of a single treatment session compared to a placebo control group were observed two 
weeks after PBM, which waned off by the time of a further assessment after four weeks. 
As stated by Hashimi et al in their article about the role of PBM in neurorehabilitation [21], 
transcranial photobiomodulation with low level red to near infrared light has already been 
used on human subjects with moderate Alzheimer’s disease, although no peer reviewed 
publications exist as of yet. This is slowly changing, with new devices being developed and 
more individuals being treated [42,43]. 
 
1.2 Minimum Effective and Maximum Tolerated Dose 
When red-to-near-infrared monochromatic or quasi-monochromatic light is supplied to the 
cytochrome oxidase in neuronal mitochondria, the photons from this light influence the proton 
gradient of the mitochondrial membrane and thus modulate ATP production. The effective 
dose of PBM appears to follow the principle of hormesis, meaning that low doses are 
stimulatory while higher doses are less effective or even counterproductive. The minimum 
effective and maximum tolerated dose has been experimentally evaluated in vitro and in vivo, 
the translation of these results to transcranial application on humans is supported by results 
from studies on transmission factors and penetration depth of red and NIR light in 
intermediate tissue. 
 
3 Hormesis 
The hermetic effect of PBM was shown by Gonzalez-Lima and Barrett in a study on rats, 
where 660 nm LED arrays with a power density of 9 mW/cm² showed the highest increase in 
cytochrome oxidase activity at a dose of 10.9 J/cm² (13.6 % increase), slightly less at the 
higher dose of 21.6 J/cm² (10.3 % increased activity) and finally a point of only non-
  
Enengl, Dungel #neverforget – PBM vs AD: A Systematic Review Page 12 of 25 
𝐹(𝑥)[
mW
cm2
]=F0[
mW
cm2
]∙e−µ[cm
−1]∙x[cm] 
(1) 
significant activity increase (3 %) at the highest dose of 32.9 J/cm² [17]. Using fluorescence-
quenching to measure neuronal oxygen consumption by looking at oxygen concentration in 
the cortex, Rojas et al report a 5 % increase in oxygen consumption at 1 J/cm² and a 16 % 
increase at a dose of 5 J/cm² when using PBM with 660 nm and an energy density of 
9 mW/cm² on rats [44]. 
 
4 Transmission 
Tedford et al quantitatively analyzed the amount of light that reaches the brain by using 
human cadaver heads, which they sectioned in such way that all of the intermittent tissues 
were kept intact and the optical energy was measured “on site” within the brain [24]. Results 
show an exponential increase in fluence rates with a linear decrease in distance between 
measurement probe and light source. An absorption coefficient for each of the measured 
wavelengths is also provided which can then be used to calculate the dose supplied to any 
point inside the brain using equation (1): 
 
 
 
With F(x) being the radiant intensity delivered to the point inside the brain in mW/cm² per 
1 mW/cm² delivered to the surface of the scalp (F0), and x being the distance between the 
surface of the scalp and the point of interest inside the brain. The value for µ is the 
absorption coefficient of the tissue at each supplied wavelength; at 660 nm it is 3.3504 cm-1, 
at 808 nm it is 2.5541 cm-1, and at 940 nm it is 3.3922 cm-1. 
 
Lychagov et al studied the NIR transmittance of the human skull and demonstrated that 
0.5 % to 5 % of the emitted light from a 1 W laser with a wavelength of 810 nm is transmitted 
in transcranial application, proving the exponential relationship between the thickness of skin 
and bone and light transmission in the NIR-range [45]. 
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Comparing the transmission of red light at 633 nm to that of near infrared light at 830 nm in a 
human cadaveric model, Jagdeo et all observed that 830 nm has a superior transmittance to 
633 nm and an occipital application allows the highest amount of energy to enter the brain, 
as Table 2 shows [46]. 
 
Table 2: Transmittance measurements of 830 nm and 633 nm light through human cadaver heads at multiple 
positions. The values stated in this table are an excerpt from the results published in [46]. 
 Control 
(10 mm of air) 
Behind skin and skull 
temporal frontal occipital 
830 nm 
33.3 mW/cm² 0.3 mW/cm² 0.71 mW/cm² 3.9 mW/cm² 
100% 0.9% 2.1% 11.7% 
633 nm 
67.5 mW/cm² <0.001 mW/cm² 0.37 mW/cm² 0.44 mW/cm² 
100% 0.0% 0.5% 0.7% 
 
 
Bungart et al investigated different wavelengths for transcranial PBM and came to the 
conclusion that a combination of 660 nm and 810 nm provides superior penetration 
compared to a combination of 980 nm and 1064 nm [26]. 
 
Once the light reaches the inside of the skull, the depth of penetration is limited by the optical 
properties of the brain tissue. Table 3 shows an excerpt of the results from Stolik et al’s ex 
vivo, post mortem measurements of the penetration depths of red and near infrared light in 
brain tissue, which suggest that light with longer wavelength will penetrate deeper into the 
tissue [47]. 
 
Table 3: Optical penetration depth of human brain tissue for different wavelengths in the red to near infrared 
spectrum of light. The values stated in this table are an excerpt from the results published in [47] 
Wavelength 632.8 nm 675 nm 780 nm 835 nm 
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Penetration Depth 
[mm ± standard error] 
n = 10 
0.92 ± 0.08 1.38 ± 0.13 2.17 ± 0.16 2.52 ± 0.19 
 
To investigate which wavelength within the optical tissue window will penetrate the deepest 
and deliver the highest dose, the values for the tissue absorption coefficient as well as the 
penetration depth were extracted from [24] and [47] and extrapolated by use of polynomial 
trend lines as shown in Figure 3. 
 
 
Figure 3: Using the literature reports on the transmittance of near infrared light through the scalp and skull, as well 
as the penetration depth inside the brain, mathematical trends are established in order to use meaningful values 
when calculating the supplied dose of wavelengths that are not covered by literature [9]. 
 
While Figure 3 suggest that a wavelength between 700 nm and 830 nm is likely to have the 
most effective and also the deepest delivery of light energy to areas inside the brain, an 
article by Wu et al claims that illumination with 730 nm and 980 nm appears to be ineffective 
when used as a modality for traumatic brain injury in mice and they suggest to use a mix of 
665 nm and 810 nm instead [48]. 
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5 Energy Density and Dosage 
Summing up the available body of research on PBM to the brain, an application time long 
enough to achieve a dose in the minimum effective range between 5 – 10 J/cm² is needed on 
a neuronal level, so, considering the exponential energy decrease during transcranial 
application, energy densities of 60 J/cm² applied to the human scalp are suggested. With an 
energy density of 250 mW/cm² this dose can be delivered within 4 minutes while PBM with a 
device supplying 100 mW/cm² would be able to deliver the required dose in 10 minutes. 
 
1.3 Outlook on a Study Design 
As a randomized, controlled, clinical intervention study, the focus needs to be on individuals 
who are at particular, specific risk to develop Alzheimer’s disease (AD), or at an early stage 
with evidence of AD neuropathology [49]. A stagnation of the MMSE-score of the treatment 
group can be chosen as the most easily detectable primary endpoint of the study. It is 
expected that the MMSE-score of the control group falls by 2 – 5 points per year [50]. 
To reach sufficient power and significance of the study, at least 15 participants per group will 
be required when assuming that the MMSE-scores of treatment– and control group differ by 
4 points at the end of a year-long trial. Even with a relatively large standard deviation of 5 
points per group this can result in a relatively large effect size of 0.8 with a level of 
significance of 0.1 and power of 0.8. Since Jacova et al have shown that in longitudinal 
studies on dementia a dropout rate of up to 55 % can be expected after 2 years [51], this 
should be taken into account by recruiting twice as many participants than were calculated to 
be sufficient, resulting in a minimum n = 30 per group. 
To achieve a higher sensitivity for any changes during the treatment protocol it is suggested 
to supplement the standard MMSE by a more sophisticated neuropsychological test battery. 
One such option could be the CERAD-NP-Test Battery, which includes the Mini-Mental State 
Examination (MMSE), word fluency testing, the Modified Boston Naming Test (MBNT), 
constructive practical testing, as well as learning, repeating, and recognizing of a word list 
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[52–61]. The pathophysiological assessment with MRI at the start of the study is useful to 
support the diagnosis of early AD. A second MRI at the end of the treatment period might 
provide more useful in combination with a sensitive algorithm that can reliably detect a 
change in brain atrophy, for example the automated MRI assessment by Desikan et al which 
has already demonstrated its usefulness as a diagnostic marker for mild cognitive 
impairment (MCI) and AD [62]. 
 
 
3 Conclusion 
When comparing the specifications of PBM devices used in the available literature, 
especially wavelength and intensity, a very inhomogeneous picture is created. One thing that 
is clear, however, is that the optical window for deep tissue penetration suggests best results 
at wavelengths in the far red and near infrared range, e.g. at 810 nm. The irradiation intensity 
of such a device needs to allow delivery of a dose of up to 60 J/cm² to the scalp within a 
reasonable period of time while providing an energy density below the risk of thermal 
damage. The amalgamation of the available literature as presented in this systematic review 
allows the assumption that photobiomodulation with the right settings can be a useful tool in 
the fight against Alzheimer’s disease. Study protocols for large placebo-controlled studies 
are readily available and we should be able to get significant results with representative 
statistical power within a year. The time to act is now – lest we forget. 
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